Map My Mole is a UK-based digital dermatology service that offers fast, affordable, and expert mole screening from the comfort of your home. Designed with convenience and early detection in mind, Map My Mole connects users with consultant dermatologists who assess skin lesions based on clear, high-resolution images submitted through a secure platform. The service aims to provide peace of mind and early intervention by identifying potentially concerning moles without the wait time or cost of traditional referrals.
Most people cannot afford private Dermatology fees, ranging from £175 to £300, and getting to see a GP takes time and often results in a referral to a specialist. The time from start to finish for a patient can be weeks. For some patients, this is an anxious wait, which is avoidable. Providing a mole screening service in a clinic with Map My Mole is aligned with the British Association of Dermatologists' teledermatology guidelines. Images are reviewed by experts in the field, and reports generated ensure patients are informed as to what the lesion represents.
If a concerning mole is imaged, the dermatologist will inform the patient, providing them with a report that can be sent to their GP to speed up any referral.
Clinics interested in offering a mole screening service should consider purchasing a robust dermoscope. This will offer the best possible images for our consultants to review, reducing requests for repeat image capture.
1. Download the Map My Mole app
2. Carry out your test submissions in training mode
3. You launch your own mole screening service
By becoming a service provider, we give you with the tools to deliver expert assessed mole reviews to your patients.
1. Our expert consultants review the submissions
2. We'll review and send the patient's report
3. Simple transparent pricing
Download the Map My Mole app to start your journey towards starting your clinic’s mole screening service.
Melanoma is the deadliest form of skin cancer, so catching it as early as possible offers the best prognosis.